Advertisement

Search Results

Advertisement



Your search for Matthew Stenger ,Matthew Stenger matches 7481 pages

Showing 5451 - 5500


breast cancer
symptom management

Acupuncture Improves Hot Flashes in Women With Breast Cancer in Italian Trial

In an Italian trial reported in the Journal of Clinical Oncology, Lesi et al found that the addition of acupuncture to enhanced self-care improved hot flashes, climacteric symptoms, and quality-of-life measures in women with breast cancer. Study Details In the trial, 190 women were randomized to...

breast cancer

Adding Ovarian Function Suppression to Tamoxifen Worsened Some Patient-Reported Outcomes in Premenopausal Women With Early Breast Cancer

Ribi et al reported in the Journal of Clinical Oncology that addition of ovarian function suppression to tamoxifen resulted in greater endocrine and sexual function symptoms among premenopausal patients with early breast cancer in the Suppression of Ovarian Function Trial (SOFT). The SOFT study...

colorectal cancer

Increased Rate of Nonoperative Management of Rectal Adenocarcinoma

A National Cancer Database analysis reported by Ellis et al in the Journal of Clinical Oncology indicates a doubling in the use of chemoradiation only in patients with nonmetastatic rectal cancer over recent years. However, current evidence is insufficient to support such nonoperative management....

colorectal cancer

Next-Generation Sequencing Assay May Permit Accurate Detection of Mismatch Repair Deficiency in Colorectal Cancer

Use of a custom next-generation sequencing assay may accurately predict mismatch repair deficiency on the basis of mutational load in colorectal cancer, according to a report by Stadler et al in the Journal of Clinical Oncology. Study Details The study involved data from 224 patients with...

breast cancer

Dutch Study Indicates Low Locoregional Recurrence in Young Women With Early-Stage Breast Cancer

Aalders et al found relatively low rates of locoregional recurrence among young (< 35 years) Dutch women undergoing surgery for unilateral invasive breast cancer between 2003 and 2008. Recurrence rates varied somewhat by biologic subtype, according to these findings reported in the Journal of...

lung cancer

Evidence of Intracranial Benefit With Crizotinib in Advanced ALK-Positive NSCLC

As reported in the Journal of Clinical Oncology, Solomon et al found that crizotinib (Xalkori) was associated with a significantly better disease control rate vs chemotherapy among patients with brain metastases in ALK-positive non–small cell lung cancer (NSCLC). Crizotinib was also...

hematologic malignancies
multiple myeloma

International Myeloma Working Group Recommendations for Myeloma-Related Renal Impairment

International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment were recently reported by Dimopoulos et al in the Journal of Clinical Oncology. Recommendations were based on review of published data through December 2015. Key recommendations...

head and neck cancer

UK Trial Shows Similar Survival With PET-CT Surveillance vs Planned Neck Dissection in Advanced Head and Neck Cancer

In a UK noninferiority trial reported in The New England Journal of Medicine, Mehanna et al found that positron-emission tomography–computed tomography (PET-CT) surveillance was associated with similar survival vs planned neck dissection in patients with stage N2 or N3 squamous cell carcinoma ...

breast cancer

Improved Detection of Breast Cancer With Ultrasound vs Tomosynthesis in Mammography-Negative Dense Breasts

Ultrasound was associated with improved incremental detection of breast cancer at screening compared with tomosynthesis in women with mammography-negative dense breasts, according to the interim findings of the Italian prospective ASTOUND study. Tagliafico et al reported these results in the...

survivorship

Racial/Ethnic Patterns of Morbidity and Mortality Among Childhood Cancer Survivors

An analysis in the Childhood Cancer Survivor Study cohort reported by Liu et al in the Journal of Clinical Oncology indicated that differences in risk for poor outcomes among black, Hispanic, and white survivors of childhood cancer were generally mediated by differences in socioeconomic status and...

breast cancer

Study Finds Decreased Use of Primary Breast-Conserving Surgery for Women in New York State

In a study reported in JAMA Surgery, Isaacs et al found that use of primary breast-conserving surgery for early-stage breast cancer has declined somewhat in recent years in New York State, most steeply among younger women. In addition, 90-day reoperation rates have declined and are lower for...

prostate cancer

Adding 6 Months of Androgen Suppression to Radiotherapy Improves Disease-Free Survival in Intermediate- and High-Risk Prostate Cancer

In the phase III EORTC 22991 trial reported in the Journal of Clinical Oncology, Bolla et al found that the addition of 6 months of androgen suppression to radiotherapy improved biochemical and clinical disease-free survival in patients with intermediate- and high-risk prostate cancer. Study...

lung cancer

Crizotinib in ROS1-Positive Metastatic Non–Small Cell Lung Cancer

On March 11, 2016, crizotinib (Xalkori) was approved for treatment of patients with metastatic non–small cell lung cancer (NSCLC) with ROS1 rearrangement–positive tumors.1,2 A U.S. Food and Drug Administration–approved test for the detection of ROS1 rearrangements in NSCLC is not currently...

neuroendocrine tumors

Everolimus Improves Progression-Free Survival in Advanced Neuroendocrine Tumors of the Lung or Gastrointestinal Tract

In a phase III trial (RADIANT-4) reported in The Lancet, James C. Yao, MD, of the University of Texas MD Anderson Cancer Center, and colleagues found that everolimus (Afinitor) and supportive care significantly prolonged progression-free survival vs placebo and supportive care in patients with...

prostate cancer

Decreased PSA Screening and Decreased Diagnosis of Early-Stage Prostate Cancer

Recent data indicate that the rate of prostate-specific antigen (PSA) screening and the rate of diagnosis of early-stage prostate cancer have decreased since a 2012 U.S. Preventive Services Task Force (USPSTF) statement (released in October 2011) gave a grade D recommendation against PSA...

lung cancer

Update of ASCEND-1 Trial Shows Ceritinib Highly Active in ALK-Rearranged NSCLC, Including Intracranial Disease

Updated results of the phase I ­ASCEND-1 trial, reported by Kim et al in The Lancet Oncology, indicate that the ALK inhibitor ceritinib (Zykadia) produced high response rates in advanced ALK-rearranged non–small cell lung cancer (NSCLC), including intracranial disease, in both patients with and...

skin cancer

Vitamin D Level Associated With Melanoma Outcome Independent of C-Reactive Protein Level

In a study reported in the Journal of Clinical Oncology, Fang et al found that lower vitamin D levels were associated with poorer outcome in patients with melanoma independent of C-reactive protein (CRP) levels. Study Details The study involved data from 1,042 prospectively observed patients with ...

breast cancer

Pathologic Complete Response to Neoadjuvant Therapy Associated With Improved Outcomes in HER2-Positive Breast Cancer

Pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer was associated with a significantly better outcome vs non–pathologic complete response, in a patient-level meta-analysis reported by Broglio et al in JAMA Oncology. Response vs No Response The study included...

gynecologic cancers

Study Reports No Overall Benefit of Adding Farletuzumab to Chemotherapy in Relapsed Ovarian Cancer, but Potential Subgroup Benefit Identified

Addition of the antifolate receptor-α antibody farletuzumab to carboplatin/taxane did not improve progression-free survival in patients with ovarian cancer in first platinum-sensitive relapse, reported Vergote et al in the Journal of Clinical Oncology. However, benefit was observed in...

lung cancer

Atezolizumab Improves Survival vs Docetaxel in Previously Treated NSCLC: Increased Benefit With Increased PD-L1 Expression

In the phase II POPLAR trial reported in The Lancet, Louis Fehrenbacher, MD, of Kaiser Permanente Medical Center, and colleagues found that the investigational anti–programmed cell death ligand 1 (PD-L1) antibody atezolizumab improved overall survival vs docetaxel in patients with non–small cell...

cns cancers

Glioblastoma Multiforme With Mismatch Repair Deficiency May Be Target for Immune Checkpoint Inhibition

Glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency was characterized by hypermutation and elevated neoantigen load—characteristics associated with response to immune checkpoint inhibitors in other settings—according to a study reported in the Journal of ...

breast cancer

Ultrasound Screening for Breast Cancer May Be Linked to Increased Detection of Invasive Tumors but More False-Positive Results

As reported in the Journal of the National Cancer Institute by Berg et al, an analysis from the American College of Radiology Imaging Network (ACRIN) 6666 study indicates that use of ultrasound in primary screening for breast cancer resulted in increased detection of invasive cancers but more...

survivorship

Effects of Chemotherapy on Pregnancy for Survivors of Childhood Cancer Treated Between 1970 and 1999

In an analysis in the Childhood Cancer Survivor Study cohort reported in The Lancet Oncology, Chow et al found that increasing doses of several alkylating agents reduced the likelihood of fathering a pregnancy among male survivors of childhood cancer, with fewer drug associations with pregnancy...

bladder cancer

Phase II Trial Shows Benefit of Adding Ramucirumab to Docetaxel in Previously Treated Advanced Urothelial Carcinoma

Adding the anti–vascular endothelial growth factor receptor 2 (VEGFR-2) antibody ramucirumab to docetaxel improved progression-free survival among previously treated patients with locally advanced or metastatic urothelial carcinoma, reported Petrylak et al in the Journal of Clinical Oncology. ...

breast cancer

Good Outcome Reported With Endocrine Therapy and Omission of Chemotherapy Based on 21-Gene Recurrence Score in Breast Cancer

Treatment with adjuvant endocrine therapy and omission of chemotherapy on the basis of a 21-gene recurrence score ≤ 11 was associated with a high 3-year disease-free survival rate in women with hormone receptor–positive, HER2-negative breast cancer, according to a trial reported in...

lung cancer

Lung Cancer Incidence and Mortality in Individuals With a Negative Low-Dose CT Prevalence Screen

In an analysis of the National Lung Screening Trial (NLST) cohort reported in The Lancet Oncology, Patz et al found that participants who had a negative low-dose computed tomography (CT) prevalence screen had a low incidence of lung cancer detected at first annual screen and exhibited reduced...

breast cancer

ASCO Endorses Cancer Care Ontario Recommendations on Decision-Making in Adjuvant Systemic Therapy for Early-Stage, Operable Breast Cancer

As reported in the Journal of Clinical Oncology by N. Lynn Henry, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and colleagues, ASCO has endorsed Cancer Care Ontario (CCO) guideline recommendations on the role of patient and disease factors in decisions on adjuvant systemic...

prostate cancer

Lower Vitamin D Levels Associated With Adverse Pathology at Prostatectomy in Men With Localized Prostate Cancer

In a study reported in the Journal of Clinical Oncology, Nyame et al found that lower serum 25-hydroxyvitamin D (25-OH D) levels were associated with an increased likelihood of adverse pathology at radical prostatectomy in men with localized prostate cancer. Study Details The cross-sectional...

breast cancer

Increased Frequency of BRCA Mutation Testing in Young Women With Breast Cancer

Rosenberg et al found that the proportion of women diagnosed with breast cancer at age ≤ 40 years who have undergone BRCA1 and BRCA2 testing has increased during recent years. These findings, which were reported in JAMA Oncology, were part of the ongoing prospective Helping Ourselves, Helping...

breast cancer

Danish Study Shows Increased Risk for Cancers in Addition to Breast Cancer in CHEK2 Mutation Heterozygotes

In a study reported in the Journal of Clinical Oncology, Näslund-Koch et al found an increased risk for cancers in addition to breast cancer in individuals heterozygous for the CHEK2*1100delC germline mutation associated with an increased breast cancer risk. CHEK2 is a cell-cycle checkpoint...

lymphoma

Greater Prognostic Value of Ki67 Index vs Cytology and Growth Pattern in Mantle Cell Lymphoma

Hoster et al found that Ki67 index had greater prognostic value than cytology or growth pattern in mantle cell lymphoma, based on data from European Mantle Cell Lymphoma Network randomized trials reported in the Journal of Clinical Oncology. A modified combination of Ki67 index and Mantle Cell...

breast cancer
supportive care

Epoetin Alfa vs Best Standard of Care in Treatment of Anemia in Patients With Metastatic Breast Cancer Receiving Chemotherapy

Use of epoetin alfa (Epogen, Procrit) vs best standard of care to treat anemia did not achieve noninferiority for investigator-assessed progression-free survival in patients receiving chemotherapy for metastatic breast cancer, reported Leyland-Jones et al in the Journal of Clinical Oncology....

bladder cancer

ASCO Endorses European Association of Urology Guideline on Muscle-Invasive and Metastatic Bladder Cancer

As reported in the Journal of Clinical Oncology by Matthew I. Milowsky, MD, of the University of North Carolina Lineberger Comprehensive Cancer Center, and colleagues, ASCO has endorsed the European Association of Urology clinical practice guideline on muscle-invasive and metastatic bladder cancer. ...

lung cancer

No Treatment Failure or Survival Benefit but Less Toxicity With Comprehensive Geriatric Assessment in Elderly Patients With Advanced NSCLC

Use of comprehensive geriatric assessment to guide therapy in elderly patients with stage IV non–small cell lung cancer (NSCLC) did not improve treatment failure–free or overall survival but was associated with slightly reduced toxicity, based on the results of the phase III...

breast cancer

Digital Breast Tomosynthesis Shows Sustained Effectiveness in Breast Cancer Screening

In a single-center retrospective study reported in JAMA Oncology, McDonald et al found that adding digital breast tomosynthesis to digital mammography reduced recall rates, increased cancer detection, and was associated with a numeric reduction in interval cancers. Study Details The analysis...

survivorship

Survivors of Adolescent and Young Adult Cancer May Be at Increased Risk of Cardiovascular Disease

Survivors of adolescent and young adult cancer were at a greater than twofold increased risk for cardiovascular disease than their counterparts without cancer, according to a study reported in the Journal of Clinical Oncology by Chao et al. Study Details The study involved data from a...

lung cancer
gastroesophageal cancer

Possible Overuse of PET to Detect Recurrence of Lung and Esophageal Cancers

Healy et al found that greater use of positron-emission tomography (PET) for detection of recurrence of lung and esophageal cancers was not associated with improved survival, suggesting potential overuse of the modality in this setting. They reported their results in the Journal of the National...

hematologic malignancies
lymphoma

Italian Study Suggests Benefit of Interim PET Response–Adapted Therapy in High-Risk Advanced Hodgkin Lymphoma

The phase II portion of the Italian HD0801 study suggests that treatment based on positron-emission tomography (PET) performed early in first-line therapy for advanced Hodgkin lymphoma may improve outcome in patients at risk of first-line treatment failure. Zinzani et al reported their findings in...

breast cancer

ASCO Guideline on Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Women With Early-Stage Invasive Breast Cancer

As reported in the Journal of Clinical Oncology by Harris et al, ASCO released a clinical practice guideline on the use of biomarkers in addition to estrogen receptor/progesterone receptor and HER2 status to guide decisions on adjuvant systemic therapy in women with early-stage invasive breast...

colorectal cancer

Japanese Trial Shows Reduced Risk of Subsequent Colorectal Adenomas and Polyps With Low-Dose Metformin

Treatment with low-dose metformin reduced the risk of metachronous colorectal adenomas and polyps over 12 months in nondiabetic patients who had undergone endoscopic polypectomy, according to a report by Higurashi et al in The Lancet Oncology. Study Details In the double-blind phase III trial,...

survivorship

Low-Magnitude, High-Frequency Mechanical Stimulation May Improve Bone Mineral Density in Young Childhood Cancer Survivors

In a small trial reported in JAMA Oncology, Mogil et al found that low-magnitude, high-frequency mechanical stimulation improved the whole-body bone mineral density score in childhood cancer survivors with low bone mineral density. Study Details In the double-blind trial, 65 survivors of...

solid tumors
hematologic malignancies
issues in oncology
survivorship

Increased Risk of Cardiovascular Disease Among Survivors of Some Adult-Onset Cancers

In a study using managed-care organization data reported in the Journal of Clinical Oncology, Armenian et al found that survivors of adult-onset multiple myeloma, non-Hodgkin lymphoma, lung/bronchus cancer, and breast cancer had an increased risk for subsequent cardiovascular disease. Study...

breast cancer
solid tumors

Neoadjuvant Nab-Paclitaxel Improves Pathologic Complete Response Rate vs Solvent-Based Paclitaxel in Early-Stage Breast Cancer

In the phase III GeparSepto-GBG 69 trial, reported in The Lancet Oncology by Untch et al, neoadjuvant nab-paclitaxel (Abraxane) improved pathologic complete response rate vs conventional solvent-based paclitaxel in women with early-stage breast cancer. Study Details In the open-label trial, 1,206 ...

solid tumors
prostate cancer

Survival Differs With Metastatic Site in Castration-Resistant Prostate Cancer

Overall survival differed according to the site of metastases in men with castration-resistant prostate cancer, according to a meta-analysis reported in the Journal of Clinical Oncology by Halabi et al. Study Details The study involved data from 8,820 men who received docetaxel chemotherapy in...

solid tumors
kidney cancer

Study Finds Apitolisib Less Effective Than Everolimus in Metastatic Renal Cell Carcinoma

As reported in the Journal of Clinical Oncology by Powles et al, the dual PI3K/mTOR inhibitor apitolisib was inferior to the mTOR inhibitor everolimus (Afinitor) in progression-free survival in a phase II trial in patients with metastatic clear cell renal cell carcinoma progressing on or after...

breast cancer

Combination Hormone Use Linked to Increased Risk of Estrogen Receptor–Positive Breast Cancer in Postmenopausal African American Women

In a study reported in the Journal of the National Cancer Institute, Rosenberg et al found that use of estrogen with progestin is associated with an increased risk of estrogen receptor–positive breast cancer in postmenopausal African American women. Study Details The study involved data on...

prostate cancer

Enzalutamide Improves Progression-Free Survival vs Bicalutamide in Nonmetastatic and Metastatic Castration-Resistant Prostate Cancer

Treatment with enzalutamide (Xtandi) tripled median progression-free survival vs bicalutamide in patients with nonmetastatic or metastatic castration-resistant prostate cancer, according to the phase II STRIVE trial reported in the Journal of Clinical Oncology by Penson et al. Study Details In...

gastroesophageal cancer

Swedish Study Shows Association of Survival Gain With Increased Surgeon Experience in Patients Undergoing Esophagectomy for Cancer

Increased surgeon experience was associated with markedly better short- and long-term survival in patients undergoing esophagectomy for esophageal cancer, according to a report by Markar et al in the Journal of Clinical Oncology. Study Details The study involved data from 1,821 patients who...

skin cancer

Assessment of Survival Impact of Atypical Responses With Pembrolizumab Treatment in Advanced Melanoma

As reported by Hodi et al in the Journal of Clinical Oncology, use of conventional Response Evaluation Criteria in Solid Tumors (RECIST) to assess response may have underestimated the benefit of treatment with the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab (Keytruda) in the...

prostate cancer

PARP Inhibitor Olaparib Produces High Response Rate in Metastatic Prostate Cancer With DNA-Repair Defects

In the TOPARP-A phase II trial reported in The New England Journal of Medicine, Joaquin Mateo, MD, of the Institute of Cancer Research and The Royal Marsden in London, and colleagues, found that the PARP inhibitor olaparib (Lynparza) produced a high response rate in patients with previously treated ...

Advertisement

Advertisement




Advertisement